STAT

As coronavirus spreads, doctors in the ER warn ‘the worst of it has not hit us yet’

STAT spoke with clinicians about what it looks like to care for #Covid19 patients — and what we might expect to happen in hospitals in the weeks to come.
Doors lead into the emergency department at St. Barnabas Hospital in New York City, one of the areas hard-hit by Covid-19 in the U.S.

Streets in cities and towns across the country are eerily quiet. Car traffic has dropped so substantially air pollution is abating. In many places, people are hunkered down indoors, trying to avoid contracting Covid-19.

But the true battle against the SARS-CoV-2 virus, which causes the disease, is playing out in hospitals that are currently — or will soon be — engulfed in an onslaught of patients struggling to breathe.

The tsunami has crashed over Seattle, parts of California, New Orleans, and New York City. In Boston and other places along the eastern seaboard, the full force of the wave hasn’t yet hit, but it’s clear it is coming soon.

Hospitals everywhere are surging their capacity, discharging any patients who can safely go home and attempting to conserve dwindling supplies of personal protective equipment, or PPE. Some are resorting to extraordinary measures — even going so far as to sanitize used N95 masks

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks